Financière de Tubize SAのEPS 1株当たり利益
Financière de Tubize SAのEPS 1株当たり利益 は何ですか。
Financière de Tubize SAのEPS 1株当たり利益 は5.85です。
EPS 1株当たり利益 の定義は何ですか。
1株当たり利益（EPS) は、当社の1株当たり利益です。それは株式の希釈を考慮に入れ、 過去12ヶ月間にカウントされます。
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EURONEXTのセクタHealth CareにおけるEPS 1株当たり利益 の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似のeps 1株当たり利益
- Jost's EngineeringのEPS 1株当たり利益 は5.84です。
- Blue StarのEPS 1株当たり利益 は5.85です。
- Apollo Micro systemsのEPS 1株当たり利益 は5.85です。
- Cambridge Technology EnterprisesのEPS 1株当たり利益 は5.85です。
- AMGENのEPS 1株当たり利益 は5.85です。
- WEX IncのEPS 1株当たり利益 は5.85です。
- Financière de Tubize SAのEPS 1株当たり利益 は5.85です。
- Northern Oil and GasのEPS 1株当たり利益 は5.86です。
- Stef S.AのEPS 1株当たり利益 は5.86です。
- Westlife DevelopmentのEPS 1株当たり利益 は5.86です。
- Northern Oil and GasのEPS 1株当たり利益 は5.86です。
- J.B. Hunt Transport ServicesのEPS 1株当たり利益 は5.86です。
- e Crit SAのEPS 1株当たり利益 は5.86です。